PROCEPT BioRobotics Securities Fraud Class Action

PROCEPT BioRobotics Corporation, a medical technology company selling surgical devices for benign prostatic hyperplasia, faces multiple securities fraud class action lawsuits. The suits allege that between February 28, 2024 and February 25, 2026, the company used an extensive discount program to incentivize customers to place bulk handpiece orders exceeding actual procedure demand, artificially inflating reported U.S. handpiece unit sales and revenues. This practice pulled forward sales from future periods, creating a glut of field inventory exceeding 10,000 units by the end of the class period. The company's stock declined sharply following disclosures: on August 6, 2025, Q2 results missed estimates, causing a 16% drop; on November 4, 2025, Q3 results missed guidance, causing a 10% drop; and on February 25, 2026, Q4 results revealed the inventory glut and a 30% sequential decline in handpiece sales, causing an 18% drop. Multiple law firms, including Bleichmar Fonti & Auld LLP, Robbins Geller Rudman & Dowd LLP, Kessler Topaz Meltzer & Check, and others, have filed or announced class actions. The lead plaintiff deadline is September 22, 2026. The case is pending in the U.S. District Court for the Northern District of California.